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Abstract
Background: Ebola is a Filovirus (FV) that induces a highly communicable and deadly hemorrhagic fever. Currently,
there are no approved vaccines to treat FV infections. Protection from FV infection requires cell mediated and
humoral immunity. Glycoprotein GP1,2 Fc Zaire, a recombinant FV human Fc fusion protein, has been shown to
confer protection against mouse adapted Zaire Ebola virus. The present studies are focused upon identifying
immunodominant epitopes using in silico methods and developing tetramers as a diagnostic reagent to detect
cell mediated immune responses to GP1,2 Fc.
Methods: The GP1,2 Ebola Zaire sequence from the 1976 outbreak was analyzed by both BIMAS and SYFPEITHI
algorithms to identify potential immuno-dominant epitopes. Several peptides were synthesized and screened in
flow-based MHC stability studies. Three candidate peptides, P8, P9 and P10, were identified and, following
immunization in Balb/c mice, all three peptides induced IFN-γ as detected by ELISpot and intracellular staining.
Results: Significantly, P8, P9 and P10 generated robust cytotoxic T-cell responses (CTL) as determined by a flow
cytometry-based Caspase assay. Antigen specific cells were also detected, using tetramers. Both P9 and P10 have
sequence homology with highly conserved regions of several strains of FV.
Conclusions: In sum, three immunodominant sequences of the Ebola GP1,2 have been identified using in silico
methods that may confer protection against mouse adapted Ebola Zaire. The development of tetramer reagents
will provide unique insight into the potency and durability of medical countermeasure vaccines for known
bioterrorism threat agents in preclinical models.
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Background
Filoviruses (FV) are single-stranded negative sense RNA
viruses that infect humans and primates. FV quickly ob-
tunds the immune system and dysregulates coagulation
[1]. The mortality rate can be up to 90 % and is species-
dependent. FV are Category A bioterrorism agents, and
there are currently no licensed vaccines or treatments. FV
induce a myriad of cellular effects that quickly overwhelm
the immune system, which results in compromised FV
antigen processing and presentation capabilities [2],
depleted T-cells and poor cytotoxic T-cell (CTL) response
[3, 4] and abrogated protective antibody production [3, 5].
The Ebola GP1,2 glycoprotein is responsible for viral
binding and entry. It is a trimer with a chalice-like form
[6]. The receptor binding region is inside the chalice and
the exterior is highly glycosylated. The receptors binding
domains and heptad repeats in the base are highly con-
served sequences among the FV species. The ability to
generate a cellular T-cell response contributes to surviv-
ing the disease. The role of T-cells in controlling Ebola
and Marburg infections has been recognized [3, 4, 7]. In
mice, CD8+ T-cell depletion and perforin knockouts
studies using FV have shown the need for CTL to
survive infection [8]. However, the CTL responses to FV
in non-human primates have not been well characterized
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given the technical challenges of working in a BSL-4
environment.
Several FV vaccine constructs have been demonstrated
to be protective in mice, guinea-pigs and non-human
primates (NHP). Irradiated Ebola virus encapsulated in
liposomes containing lipid A elicited GP1,2 specific CTL
response [9] and attenuated Venezuelan equine enceph-
alitis virus replicons expressing GP1,2 [10] showed pro-
tective responses in mice. An improved vaccination
strategy using DNA plasmids expressing mixtures of
different GP1,2 along with nucleoprotein (NP) and fur-
ther boosting with recombinant adenovirus expressing
GP1,2 proved effective in eliciting protection against live
Ebola virus challenge in cynomolgus macaques [11].
Vesicular stomatitis virus based vaccines encoding GP1,2
protected NHP from Bundibugyo Ebola virus [12].
Respiratory tract immunization of NHP with a Newcastle
disease virus-vectored vaccine showed protective response
against Ebola virus challenge [13]. Live attenuated rabies
virus vaccine expressing GP1,2 has been proposed for its
safe use for vaccination in humans and wildlife [14]. Also,
the recombinant protein, Ebola Zaire GP1,2 Fc, protected
mice from lethal mouse adapted Ebola Zaire challenge [15].
Identifying immunodominant epitopes provides critical
insight into the mechanism of protection to FV. Immuno-
dominant peptides of EBOV GP1,2 [16–19] and Lassa GP1,2
and Ebola nucleoprotein have been determined [20, 21].
Importantly, MHC tetramer technology has simplified the
study of antigen-specific CTLs to determine the func-
tional sensitivities of T-cell populations [22]. Tetramers
are fluorochrome-conjugated peptide–major histocom-
patibility complex (pMHC) multimers that are used in
the study of antigen-specific T-cells by enabling their
visualization, enumeration, phenotypic characterization
and have been extensively used to track T-cells ex-vivo
following vaccination or during viral infection [23]. As
a result, tetramers can be used as surrogate markers of cell
mediated immunity. On the other hand, B-cell mediated
responses, especially antibodies specific to GP1,2 co-
related with protection in NHPs and mice [24, 25]. The
postexposure antibody treatments demonstrated to pro-
tect NHPs from filovirus infection [26]. In sum, develop-
ment of effective Ebola vaccine would require both
protective CTLs as well as a robust antibody response to
ensure survival to lethal Ebola challenge.
In the present study we identified immunodominant
peptides of the GP1,2 from Ebola Zaire in Balb/C mice
for the KD MHC using in silico algorithms. The objective
was to generate tetramers that can be used to follow
CTL. Peptide candidates were screened and three
peptides stabilized the KD MHC: P8, EYLFEVDNL,
amino acids (aa) 231–240; P9, LFLRATTEL, aa 571–579;
and P10, LYDRLASTV, aa 161–169. Splenocytes from
peptide immunized mice generated IFN-γ upon in vitro
re-stimulation and induced apoptosis in peptide sensi-
tized targets. Tetramers for all three peptides were gen-
erated that detected antigen specific T-cells following
immunization. Significantly, two of the three epitopes are
conserved within FV which suggests that tetramer re-
agents will be useful in following cell mediated responses
to Zaire vaccine candidates such as GP1,2 recombinant
proteins, GP1,2 expressing virus like particles, recombinant
VSV, Adenoviruses and GP1,2 DNA vaccines.
Results
In silico predictions of GP1,2 immuno-dominant epitopes
The GP1,2 sequence of Ebola Zaire was analyzed using
both BIMAS and SYFPEITHI algorithms to identify pep-
tides that may possess high binding affinity to KD MHC.
Three peptides scored better than 150 for BIMAS and
20 for SYFPEITHI, and these are presented in Table 1.
These were P8, EYLFEVDNL amino acids (AA) 231–240
[16]; P9, LFLRATTEL AA 571–579; and P10, LYDR-
LASTV AA 161–169 [17]. These peptides were synthe-
sized for further characterization. This is the first report
of evaluation of immunological response analysis for
peptide P9. The peptide P9 (LFLRATTEL), was identi-
fied in 2009 by Kent et al., (Kent J. Weinhold, Georgia
D. Tomaras, Yongting Cai, Kelly Plonk, Scott Pruitt,
Smita K.Nair) and was submitted to Immune Epitope
Database and analysis Resource and can be found at the
following link, http://www.iedb.org/epId/91636. Peptides
P8 and P10 were previously reported by Dowling et al.
[16] and Warfield et al. [17] respectively.
MHC stability studies using RMAS KD cells
The peptides identified above using the BIMAS and
SYFPEITHI algorithms were screened using a MHC sta-
bility assay. Peptides were incubated with TAP deficient
RMAS cells that expressed the Class I molecule, KD. Fol-
lowing an overnight incubation, KD was assessed in a
flow-based assay. The MFI for the three peptides is shown
in Fig. 1. All three peptides induced a significant increase
Table 1 In silico predictions of Ebola Zaire GP1,2 epitopes
Protein sequence Start position Peptide BIMAS SYFPEITHI
Score Score
Ebola Zaire GP 231 EYLFEVDNL 4000 23
676 AA (P8)




161 LYDRLASTV 600 22
(P10)
GP1,2 from Ebola Zaire was analyzed both by BIMAS and SYFPEITHI. Nonomer
peptides that scored greater or equal to 150 on BIMAS and 22 on SYFPEITHI
were subjected to further evaluation
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in the MFI, as compared to the isotype control (6 ± 0). P8
was 45 ± 4, P9 was 19 ± 5, and P10 was 17.6 ± 0.5.
These results suggest that P8, P9 and P10 can stabilize
the KD MHC. P8 originates from the highly variable and
glycosylated region of GP1,2. P9 is located in the con-
served region of the tail that is responsible for injecting
the virus into the cytoplasm. P10 is found in the con-
served region that mediates GP1,2 receptor binding to
cellular receptors. The sites of these peptides are shown
in Fig. 2 and are overlaid on the GP1,2 sequences for
Bundibugyo, Tai Forest, Zaire, Reston, Sudan and
Marburg viruses.
A) P8 B) P9 C) P10
Isotype 
Control
Fig. 1 Stabilization of KD expression IN KD RMAS cells by Ebola GP1,2 peptides. GP1,2 Ebola Zaire, NCBI accession number AAB81004.1, was analyzed by
both BIMAS and SYFPEITHI. The GP1,2 protein sequence was divided into segments of nine amino acid that overlapped by eight amino acids. Peptides
that scored better than >150 in BIMAS and >24 in SYFPEITHI were selected for further study. BD FACS SCAN was used to assess peptide stabilization of
MHC expressed on KD RMAS cells. The heavy line represents isotype control. The results are representative of three independent experiments
Fig. 2 Sequence alignment of GP1,2 from Ebola Zaire (AAA96744.1), Sudan virus (AAP88031.1), Bundibugyo (YP_003815435), Tai Forest (YP_003815426.1),
Reston (Q66799.1), and Marburg Lake Victoria (P35254.1). Clustal W alignments were performed and highlights were added via Boxshade. Amino acids
that are identical are shaded black while chemically similar amino acids are grey. The location of peptides P8, P9 and P10 are indicated by the boxes.
P8 is in a highly variable region while P9 and P10 are located in highly conserved regions for cytosolic entry and cellular recognition, respectively
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ELISpot analysis of peptides
An ELISpot for IFN-γ was used to assess the immuno-
dominant potential of the peptides identified in the KD
stability studies. To assess immunogenic potential, mice
were immunized with P8, P9 or P10 and an IFN-γ ELI-
Spot was performed. As shown in Fig. 3, the P8 ELISpot
response was less robust when compared to P9 and P10.
For P10, the ELISpot response was concentration-
dependent and the maximum response for the peptide
was 100 μM.
Intracellular staining for IFN-γ
To clarify the cellular identity of IFN-γ secretions, intra-
cellular staining (ICS) was performed using splenocytes
from peptide immunized mice. A robust signal for IFN-γ
was seen for all three peptides that were predominately in
the CD8+ T-cells as shown in Fig. 4. In sum, the three
peptides induced IFN-γ expression in CD8+ T-cells, which
was around 2 % as compared to the control of 0.25 %.
Tetramer analysis
To follow the development of CTL cells, Tetramer re-
agents for KD MHC were generated for P8, P9 and P10.
Mice were immunized with peptides as described above
and splenocytes were prepared. Splenocytes were stained
with tetramer and counterstained with CD3 PerCP and
CD8 FITC. The results are shown in Fig. 5. In the CD8+
T-cell gated population, 1.7 % of cells were positive for
P8 tetramer, 0.6 % of cells were positive for P9 tetramer,
and 0.3 % of cells were positive for P10 tetramer. Clearly,
antigen specific cells can be induced by P8, P9 and P10
and tetramers bound to splenocytes can be detected and
amplified by sorting. Next, cells were sorted on the basis
of tetramer binding. The post-sort results are also shown
in Fig. 5. The frequency of tetramer positive cells after
sorting was increased to 48 % (28 fold), 35 % (58 fold)
and 59 % (196 fold) for P8, P9 and P10, respectively.
CTL analysis
Finally, the ability of P8, P9 and P10 to generate func-
tional CTL was examined. A flow based assay was used
to follow Caspase 3 generation in KD targets. Spleno-
cytes from peptide immunized mice were re-stimulated
in vitro with the corresponding peptides. KD targets were
incubated overnight with peptides. The effector cells and
targets were mixed and the Caspase 3 expression was
followed by flow cytometry as shown in Fig. 6. For all three
peptides, Caspase generation was seen that was dependent
upon the E: T ratio. With all three peptides, significant
killing was seen at E: T ratios of 1:1, 0.5:1, 0.25:1 and
0.125:1. The robust lysis implies that P8, P9 and P10 may
function in vivo as immunodominant epitopes.
Discussion
In the current study, several hundred Ebola GP1,2 Zaire
sequences were examined using in silico techniques.
Nanomers that scored higher than 22 on SYFPEITHI or
150 on BIMAS are shown in Table 1. The SYFPEITHI
algorithm provides a score based upon the pattern of
amino acid sequences that preferentially bind to the
MHC. The BIMAS score is based on binding affinities of
single amino acids of the peptide, with each amino acid
weighted the same, thereby providing an overall affinity
to MHC. Following their synthesis, MHC stability was ex-
amined using KD expressing RMAS cells. The peptides
were P8, EYLFEVDNL aa 231–240; P9, LFLRATTEL, aa
571–580 and P10, LYDRLASTV aa 161–170. P8 and
P10 are from regions that are highly conserved across
species Zaire Mayinga, Zaire Kikwit, Cote-d-Ivoire,




Fig. 3 IFN-γ Elispot responses by splenocytes were evaluated following immunization with Ebola Zaire GP1,2 peptides. Mice were immunized and
boosted 7 days after initial immunization. Splenocytes were re-stimulated in vitro with peptide overnight. The mean IFN- γ Elispots/106 splenocytes
+/− the S.E. is presented. The results are representative of three independent experiments. Asterisks indicate statistically significant IFN- γ increase in
peptide-exposed cells at 100 mm concentration compared with those cells treated with 0.1 mm peptide (* = p <0.05)















Fig. 5 Tetramer staining of immunized splencocytes. Splenocytes from peptide immunized animals were stained with KD tetramers prepared with
P8, P9, P10 or Adjuvant (mock-infected). The cells were counter stained with CD8 FITC and CD3 PerCP, then fixed. The stained cells were analyzed
in a FACS ARIA. Tetramer positive cells were sorted and re-analyzed. Pre-sort and Post sorted tetramer positive cells are shown in figure. The
results are representative of three independent experiments
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Fig. 4 Induction of intracellular IFN- γ production following immunization with P8, P9 and P10. Splenocytes from peptide immunized animals
were cultured for 24 h in vitro with respective peptide. Cells were collected, washed, stained with CD3ε PerCP and anti-CD 8 FITC and fixed. The
cells were further stained with anti-IFN-γ antibody and were analyzed using BD FACS Canto. The results are represented as mean +/− S.E. of three
independent experiments. Asterisks indicate statistically significant IFN-γ increase in peptide-exposed cells compared with those untreated cells
(* = p <0.05)
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Marburg Popp [6]. P8 [18, 19] and P10 [17–19] have
been previously reported as CTL epitopes in Zaire EBOV
GP1,2; however we have performed immunological ana-
lysis of a immune-dominant P9 peptide, which has been
submitted by Kent et al. to http://www.iedb.org/epId/
91636. As shown in Fig. 1, all three stabilized expression
of KD MHC, which is crucial for immunodominant
epitopes.
ELISpot identifies cells secreting cytokines and has a
limit of detection as low as 1:106 [27, 28]. The ELISpot
also provides a convenient means of estimating the fre-
quencies of IFN-γ producing cells [29]. Using a rabies
vaccine expressing Ebola virus glycoprotein, a strong
ELISpot response was seen in mice using peptide pools
of GP1,2 [14]. In the study, the peptides P8, P9 and P10
induced IFN-γ release. However as shown in Fig. 2, in
contrast to the KD stability studies, P10 elicited the
greatest response followed by P9 and P8.
As shown in Fig. 3, all three peptides induced IFN-γ in
CD8+ T-cells, implying that these peptides may provide
significant protection against Ebola. Lassa GP1,2 peptide
also elicited a IFN-γ signal in HLA-A2.1 transgenic mice
[20]. The ICS results were highly consistent with the
ELISpot data.
Class I tetramers permit the rapid assessment of anti-
gen specific CD8+ T-cells which is essential in monitor-
ing immune responses to infections as well as vaccine
development [23]. Tetramers can often detect antigen
specific T-cells that are of low abundance and undetectable
by functional studies such as ELISpot and ICS [30–33].
Tetramers were developed for nucleoprotein epitopes of
Ebola Zaire [8]. In this study, peptides P8, P9 and P10 were
used to generate Class I Tetramers (synthesized at NIAID).
When mice were immunized with the peptides, a specific
staining for each tetramer was observed as shown in Fig. 4.
Furthermore, we sorted the cells based upon tetramer
staining which greatly amplified the detection of epitope
specific CD8+ T-cell population. This demonstrates the
utility of the tetramer reagents that will greatly assist in
the ongoing studies using GP1,2 from Ebola Zaire.
We have used a non-radioactive flow-based assay to
detect apoptosis in peptide sensitized, DDAO labeled KD
RMAS cells [34]. Most importantly, the flow-based Cas-
pase 3 generation assay is 10–50 times more sensitive
than the chromium release assay [34]. As shown in Fig. 5,
we noted Caspase 3 in DDAO labeled targets at the low
Effector to Target ratio of 1:1. The Caspase generation is
a function of effector cell number and was reduced
linearly for all three peptides as the number of effectors
decreased. The Caspase-3 expression shown in Fig. 6
and the IFN-γ expression observed in ICS staining as
seen in Fig. 4 were comparable and support each other.
These results suggest that the peptides may play a sig-
nificant role during vaccination and protection of Ebola
infection. The results from the present study are consist-
ent with earlier studies [9]. In Rao et al., the peptides P1
and P2 were identified using classical CTL assays to Ebola
Zaire. Both P1 and P2 were assessed using liposomes









































Fig. 6 CTL response induced by peptides P8, P9, and P10. Splenocytes from immunized animals were cultured for 5 days in vitro with peptide, collected
and counted. In parallel, KD cells were incubated overnight with P8, P9, P10 or adjuvant (mock control), washed and then labeled with DDAO cell tracker.
Effector and target cells were mixed and incubated for 4 h in the indicated ratios and fixed. The cells were stained with anti-cleaved
Caspase-3 PE and analyzed by flow cytometry using a FACS Canto. The mean percentage of Caspase positive KD cells +/− the SE is
presented. The results are representative of three independent experiments. Asterisks indicate statistically significant increase in Caspase -3 positive cells
compared with those Caspase positive cells in mock (* = p <0.05)
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containing Ebola Zaire, though the E:T ratio used by Rao
et al. was much higher than used in the present experi-
ments. CTL generated by peptides have also been demon-
strated for Ebola Zaire NP [21] and Lassa GP1,2 peptides
[20] using a Chromium release assay.
It has been shown that GP1,2 can confer protection
against mouse adapted Ebola [15]. It would be of signifi-
cant interest to determine the immunogenicity of P8, P9
and P10, the immunodominant epitopes in GP1,2. Taking
a step further, we have immunized Balb/c mice with
GP1,2, the protein responsible for both cell mediated and
humoral immunity. As shown in Fig. 7, all the peptides
in our study specifically induce Caspase-3 expression
(killing) in DDAO-labeled target cells. Fig. 8 shows in-
duction of IFN-γ in CD8+ T-cells, when stimulated with
peptides. This indicates that immunizing with an Ebola
virus Glycoprotein, in a whole protein form, can poten-
tially promote vaccine induced protective immunity.
This experiment further confirms the immune-dominant
potential of these peptides. Recently, a recombinant Ves-
icular Stomatitis Virus based vaccine, expressing Zaire-
GP1,2 was found to be 100 % successful in phase I trail
in Africa. Hence, identifying immune-dominant peptide
specific protective CTLs in these protected vaccinees,
using tetramer technology for human CD8+ T-cells,
would aid in development of peptide-based vaccines
against the deadly disease. Additionally, we would also
like to extend our studies to explore the cell-mediated
responses in transgenic mice expressing mamu-A-01
transgene, a Rhesus HLA to Ebola GP1,2. The chal-
lenge is in extending promising rodent studies to non-
human primates [35].
Conclusions
In this paper, we have identified three immune-dominant
KD epitopes of GP1,2 using in silico methods and evaluated
their immunogenicity through in vitro and in vivo assays.
Furthermore, we developed tetramers, which detect Ebola
specific T-cells. These tetramer reagents will significantly
contribute in evaluating cell-mediated responses to in-
fection and also in determining the efficacy of pro-
spective vaccine candidates in the field of Ebola vaccine
research.
Methods
In silico epitope prediction
The amino acid sequence for the Ebola Zaire GP1,2
Mayinga 1976 strain, (NCBI accession number: AAB
81004), was used in these experiments. The sequence,
676 aa long, was analyzed first using the BIMAS algo-
rithm (http://www-bimas.cit.nih.gov/) followed by the
SYFPEITHI algorithm (http://www.syfpeithi.de) for the
KD MHC of Balb/c [Parker, 1994 13 /id]. The following
Filoviruses were used for sequence alignment of GP1,2,
and their NCBI accession numbers are indicated: Zaire
Ebola virus (AAA96744.1); Sudan Ebola virus (AAP
88031.1); Ebola Bundibugyo (YP_003815435); Tai Forest







































Fig. 7 CTL response induced by GP1,2 immunization. Splenocytes from immunized animals were cultured for 5 days in vitro with P8, P9 and P10
peptides, for the expansion of peptide specific CTLs, that were collected and counted. In parallel, KD cells were incubated overnight with P8, P9,
P10 or adjuvant (mock control), washed and then labeled with DDAO cell tracker. Effector and target cells were mixed and incubated for 4 h in
the indicated ratios and fixed. The cells were then stained with anti-cleaved Caspase-3 PE and analyzed by flow cytometers, using a FACS Canto. The
mean percentage of Caspase positive KD cells +/− the SE is presented. The results are representative of three independent experiments. Asterisks
indicate statistically significant increase in Caspase -3 positive cells compared with those Caspase-3 positive cells in mock (* = p < 0.05)
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(YP_003815426.1); Reston Ebola virus (Q66799.1) and
Lake Victoria Marburgvirus (P35254.1).
Peptides
Peptides were synthesized by New England Peptide
(Gardner, MA), using standard methodology. Peptides
were >95 % pure. They were re-constituted in de-ionized
water and kept frozen at −20 °C until use. All peptides
were diluted in culture media: RPMI-1640 (Gibco, Green
Island, NY) containing 10 % (v/v) heat-inactivated fetal
bovine serum (FBS), 1 % (v/v) antibiotic-antimycotic
solution (Gibco) and 2 mM glutamine (Gibco).
Mice
Balb/c female mice, 4–6 weeks of age, were obtained
from the National Cancer Institute, Frederick, MD.
Upon receipt, the mice were held for 7 days for acclima-
tion in an Association for Assessment and Accreditation
of Laboratory Animal Care International -approved facility
with ad libitum access to food and water. All experiments
were performed with the approval of the Food and Drug
Administration, Center for Drug and Radiological Health
Institutional Animal Care and Use Committee.
Immunization
Mice were immunized intra-peritoneally with 100 μg
of peptide and 140 μg of Hepatitis B virus helper pep-
tide, TPPAYRPPNAPIL in 100 μl of Seppic Montanide
(Fairfield, NJ). Initially, the peptides were diluted in
sterile PBS and mixed with an equal volume of Seppic
Montanide. Mice were boosted with equivalent dose
on day 7. One week later, the mice were sacrificed with
CO2 and their spleens were harvested. The spleens were
placed in pre-warmed Hank’s Balanced Salt Solution
(HBSS) and processed to single cell suspensions. The
erythrocytes were lysed with Ammonium Chloride potas-
sium lysing buffer (Gibco) and the cells were washed once
and re-suspended in media. For GP1,2 immunization,
100 μg GP1,2 -Fc (Kindly, provided by Dr. Krishnamurthy
Konduru, CBER/FDA) and 140 μg of Hepatitis B virus
helper peptide, TPPAYRPPNAPIL in 100 μl of Seppic
Montanide. Mice were boosted with equivalent dose on
day 10. Ten days later, the mice were sacrificed with CO2
and their spleens were harvested. Spleens were then
processed to single cell suspension as described above.
ELISpot
The frequency of interferon-γ (IFN-γ) producing cells
was measured by ELISpot. Briefly, the Immobilon®-P
polyvinylidene fluoride plates (Millipore, Billerica, MA)
were treated with 15 μl 33 % ethanol (Pharmco, Shelby-
ville, KY) for 1 min, and washed 5 times with sterile
H2O. These plates were coated with 0.1 M carbonate
Buffer (Sigma) containing anti-mouse IFN-γ (Mabtech,
Mariemont, OH), 15 μg/ml and refrigerated overnight at
4 °C. The plate was washed 3 times in sterile PBS. The
plate was incubated with blocking buffer using 1 % Bo-
vine Serum Albumin in HBSS for 2 h at 37 °C in culture.
105 splenocytes per well were plated within 1 h of har-
vest from peptide immunized mice and incubated with
selected dilutions of peptide in six replicate wells. PMA
and ionomycin treated splenocytes were used as a posi-
tive control in all experiments. Following an overnight
incubation at 37 °C, the media was removed and the
plate was incubated with 200 μl wash buffer (PBS con-
taining 0.01 % Tween-20, Sigma) for 10 min at RT. Next,
the plate was washed three times with wash buffer for
1 min at RT. The biotinylated detecting antibody (Mab-
tech) diluted 1:1000 in freshly made and filtered 1 % BSA/
PBS was added and the plate was incubated for 2 h at RT.
The plate was washed 3 times with wash buffer and twice
with PBS. Next, streptavidin HRP (Jackson Immuno Re-
search, West Grove, PA) diluted 1:500 in PBS containing
0.5 % FCS in PBS was added and the plate was incubated
for 1 h at RT. Following washing, 50 μl TMB substrate
(Mabtech) was added per well. Washing with deionized
water stopped the reaction immediately. After drying,
the plate was analyzed using an AID plate reader
(Autoimmun Diagnostika, Strassberg, Germany).
Intracellular cytokine staining
Splenocytes from peptide immunized mice were incu-
bated with 1 μM peptide for 1 h [19]. Next, Brefeldin A
(Sigma) was diluted 1:1000 and was added for overnight
Unstim-
ulated





























Fig. 8 Induction of intracellular IFN-γ production following
immunization with GP1,2-Fc. Splenocytes from GP1,2-Fc immunized
animals were cultured for 24 h in vitro with P8, P9 and P10 peptides.
Cells were collected, washed, stained with CD3ε PerCP and anti-CD 8
FITC and fixed. The cells were further stained with anti-IFN-γ antibody
and were analyzed using BD FACS Canto. The results are represented
as mean +/− S.E. of two independent experiments
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stimulation. The cells were harvested and washed with
cold staining buffer. Staining buffer is composed of
HBSS (Gibco) and 3 % FCS [27]. The cells were blocked
with anti-Fc (BD) for 30 min on ice, followed by a wash
with FACS buffer. The cells were stained for CD8 FITC
(BD) for 1 h on ice and then washed twice with FACS
buffer. Next, the cells were fixed with BD Cytofix for
20 min at RT. The cells were either kept at 4 °C or proc-
essed for intracellular staining. To stain, the cells were re-
suspended in permeabilization buffer (BD) and washed
once with FACS buffer. The cells were then stained for
1 h with PE labeled anti-IFN-γ (BD). Following staining,
the cells were washed twice with the permeabilization
buffer and re-suspended in FACS buffer. The cells were
analyzed by flow cytometry in a FACS Canto using DIVA
software.
Cleaved active caspase-3 and flow cytometry based CTL
assay
Splenocytes were cultured with 1 μM of the appropriate
peptide for 5 days in culture media supplemented with
10 % T-stim (BD). The cultures were harvested and the
cells were centrifuged on Lympholyte M cell separation
media (Cedarlane Laboratories, Burlington, NC), washed
once in media and adjusted to 106 cells/ml.
KD TAP deficient RMAS cells (a generous gift from
Eric G. Pamer, Memorial Sloan Kettering Cancer Cen-
ter), were maintained in RPMI-10. KD cells were incu-
bated overnight with 1 μM of the appropriate peptide.
KD cells were harvested, adjusted to 5 × 106 cells/ml
and labeled with 0.6 μM 1,3-dichloro-7-hydroxy-9,9-di-
methyl-2(9H)-Acridinone (DDAO; Invitrogen, Grand
Island, NY) for 15 min at 37 °C. The reaction was stopped
with the addition of complete media. The KD cells were
washed once with RPMI-10 and adjusted to 106 cells/ml.
For the Caspase 3 Assay, DDAO labeled peptide
pulsed KD cells, 105 in 100 μl of RPMI-10, known as
“targets” (T) were added to a round bottom plate [21].
Next, “effector” (E) cells, splenocytes, were added. The
E: T ratio was varied from 1:1 to 0.1:1. The plate was
spun at 200 rpm for 1 min and the cultures were incu-
bated for 4 h at 37 °C. The cells were washed twice with
FACS buffer. The cells were then permeabilized using
the cytofix/cytoperm kit according to the manufacturer’s
instruction (BD Biosciences) and stained with PE labeled
rabbit-anti mouse cleaved Caspase 3 (CC3) at 1:100 dilu-
tion for 60 min (BD Biosciences). Cells were analyzed on
a FACS Canto using FACS DIVA software.
Peptide stabilization of MHC
KD cells were washed twice in serum free AIM V media
(Gibco), adjusted to 2 × 106 cells per ml and 80 μL was
dispensed into each well of a round bottom plate. The
peptides, 50 μM, were added to the plate [16]. The plate
was incubated for 18 h and then washed with FACS
buffer. FITC labeled BB7.2 antibody (BD), diluted to
500 ng/ml, was added for 30 min. After washing the
cells were analyzed via FACSCAN.
Tetramer staining and FACS ARIA sorting
Splenocytes, (10 × 106), from immunized animals were
re-suspended in 200 μl sort buffer which contained 2 %
FCS and 0.2 % Na azide (Sigma) in HBSS (FACS buffer).
Fc receptors were blocked with the addition of anti-Fc
(BD) for 20 min. Next, 2 μl of peptide specific PE-
labeled tetramer (NIAID Tetramer facility, Atlanta, GA)
was added and the cells were incubated for 1 h at 37 °C.
After one wash with FACS buffer, the cells were stained
with anti-CD3 FITC and CD8 PerCp. Following washing,
the cells were fixed as described above and were sorted
on a FACS ARIA with 106 events acquired.
Statistics
All values are expressed as mean ± SD. Individual experi-
ments were performed in at least triplicate (n ≥3). The
software package Instat 2 (Graph Pad Prism, version 5;
Graph Pad Software, San Diego, CA) was used for statis-
tical analysis of data. Significant differences between
groups were determined using student’s t-test or one-
way analysis of variance (one-way ANOVA) followed by
using either a Dunnett’s or Bonferroni’s post-hoc test to
compare the significance of differences between means.
A p-value <0.05 was considered significant.
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